PFKFB3 inhibition tightens the vascular barrier by reducing VE-cadherin endocytosis in ECs and reduces glycolysis to make cells more quiescent and adherent (by upregulating N-cadherin); it also reduces NF-κB signaling to reduce the expression of cancer cell adhesion molecules in ECs. The gene discussed is CDH2; the disease is cancer.